Our Company

Orion Corporation is a Finnish stock exchange company established in 1917 which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets.

Orion operations are carried out in four business areas:
- Proprietary products focusing on the development of original preparations
- Specialty products which develop and produce generics
- Animal Health
- Active Pharmaceutical Ingredients manufactured by Fermion Oy

Orion Pharma UK Ltd is a subsidiary of Orion Corporation Finland, oriented towards research and development of pharmaceuticals.  Orion Pharma's net sales exceeded half a billion Euros in 2004, generated with a personnel of about 2,600 people.  

Therapy Areas
Orion Pharma concentrates its pharmaceutical research and business operations on three strategic core therapy areas:
- Central nervous system disorders
- Cardiovascular Diseases and Critical Care
- Hormone Therapy and Urology

Orion Pharma's pharmaceutical research operations focus on the first phases of the research process, the pre-clinical research with the objective of creating new drug molecules for the subsequent clinical trials with patients. Products include Stalevo; Comtess; Indivina and Tridestra.The most recent invention is the ORM-10921 molecule for the treatment of schizophrenia, entering the Phase I clinical trials after several years of pre-clinical research.

The value of "Mutual Trust and Respect" is indispensable in guiding our endeavour of providing innovative products and best quality service to patients, healthcare professionals and the community.